(Q37498272)

20 August 2017

1 reference

title

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (English)

1 reference

20 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

F J Giles

1

1 reference

20 August 2017

M O'Dwyer

series ordinal

2

1 reference

20 August 2017

R Swords

series ordinal

3

1 reference

20 August 2017

language of work or name

1 reference

28 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

23

1 reference

20 August 2017

issue

10

1 reference

20 August 2017

page(s)

1698-1707

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

How I treat chronic myeloid leukemia in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

An efficient rapid system for profiling the cellular activities of molecular libraries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Src family tyrosine kinases and growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Independent and opposing roles for Btk and lyn in B and myeloid signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Lyn kinase promotes erythroblast expansion and late-stage development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Clinical and molecular characteristics of malignant transformation of low-grade glioma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Global amplification polymerase chain reaction reveals novel transitional stages during osteoprogenitor differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

To go or not to go: Migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

The cell survival signal Akt is differentially activated by PDGF-BB, EGF, and FGF-2 in osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

BNP as a marker of the heart failure in the treatment of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Calpain: a role in cell transformation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Role of the KIT protooncogene in normal and malignant human hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

The biology of stem cell factor and its receptor C-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Imatinib therapy for chronic myeloid leukemia: where do we go now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Altered Bone and Mineral Metabolism in Patients Receiving Imatinib Mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

The effect of systemically administered PDGF-BB on the rodent skeleton

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor beta

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

PDGF receptors as targets in tumor treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Tyrosine kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Expression of c-kit and kit ligand proteins in normal human tissues

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Comment to: Hepcidin: from discovery to differential diagnosis. Haematologica 2008; 93:90-7

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2009.111

7 January 2021

Identifiers

DOI

10.1038/LEU.2009.111

1 reference

20 August 2017

1 reference